Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments

Eli Lilly and Co. (NYSE:LLY) shares are up during Monday’s premarket session following the company’s announcement of its acquisition of Orna Therapeutics, which aims to advance cell therapies.

The strategic move is seen as a significant step in enhancing Lilly’s capabilities in genetic medicine, adding pressure as broader markets edged lower.

Lilly’s $2.4 Billion Orna Acquisition

Under the terms of the agreement, Lilly will acquire Orna for up to $2.4 billion, which includes an upfront payment and additional payments tied to clinical development milestones.

Orna is focused on engineering immune cells in vivo, with its lead program targeting B cell-driven autoimmune diseases through a circular RNA platform.

Orna’s lead program is ORN-252, a clinical trial-ready, CD19-targeting in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases.

The press release on Monday noted that experiments to date suggest that Orna’s circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms.

Meanwhile, the broader market experienced a mixed performance on the previous trading day, with the S&P 500 down by 0.16% and the healthcare sector gaining 0.35%.

Lilly’s stock is moving higher even as major indices faced declines.

Eli Lilly’s Short-Term Weakness vs. Long-Term Gain

The stock is currently trading 5.2% below its 20-day simple moving average (SMA) and 3.8% below its 100-day SMA, indicating some short-term weakness. Shares have increased approximately 71.9% over the past 12 months and are currently positioned closer to their 52-week highs than lows.

The RSI is at 44.45, which is considered neutral territory, while MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

• Key Resistance: $1133.50
• Key Support: $1020.00

Analyst Consensus & Recent Actions:

The stock carries a Buy Rating with an average price forecast of $1077.30. Recent analyst moves include:

• JP Morgan: Overweight (Raises Target to $1300.00) (Feb. 5)
• Cantor Fitzgerald: Overweight (Raises Target to $1205.00) (Feb. 5)
• Wells Fargo: Overweight (Raises Target to $1280.00) (Feb. 5)

Valuation Insight: While the stock trades at a premium P/E multiple, the strong consensus and rising estimates suggest analysts view the growth prospects as justification for the 5% upside to analyst targets.

LLY Price Action: Eli Lilly stock is up 1.13% at $1070.11 during premarket trading on Monday, according to Benzinga Pro data.

Photo via Shutterstock